Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbbVieABBV -0.54%77 Equity-to-Asset is -0.04 as of Jun. 2026. GuruFocus rates ABBV with a GF Score™ of 77/100 and a GF Value™ of $218.61 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,006 Drug Manufacturers companies, AbbVie ranks worse than 92.05% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AbbVie's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $-5,935 Mil. AbbVie's Total Assets for the quarter that ended in Jun. 2026 was $135,115 Mil.
Therefore, AbbVie's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was -0.04.
The historical rank and industry rank for AbbVie's Equity-to-Asset or its related term are showing as below:
ABBV'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.15 Med: 0.07 Max: 0.12
Current: -0.04
During the past 13 years, the highest Equity to Asset Ratio of AbbVie was 0.12. The lowest was -0.15. And the median was 0.07.
ABBV's Equity-to-Asset is ranked worse than 92.05% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs ABBV: -0.04
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
AbbVie Equity-to-Asset Related Terms
AbbVie Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for AbbVie's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABBV vs MRK, JNJ, AMGN: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, AbbVie's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where AbbVie's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
AbbVie's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie (ABBV) has a Equity-to-Asset of -0.04 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AbbVie and its competitors. According to the industry distribution chart, AbbVie ranks #926 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 92%.
Is AbbVie's Equity-to-Asset too high?
AbbVie's current Equity-to-Asset is -0.04. Based on the distribution chart, AbbVie ranks #926 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AbbVie has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Equity-to-Asset compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #926 out of 1006 companies for Equity-to-Asset. This places AbbVie in the lower half of its industry. The industry median Equity-to-Asset is 0.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AbbVie and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbbVie's current Equity-to-Asset is -0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is $218.61, compared to a current price of $249.46 — trading 14.1% above its estimated fair value. The current Equity-to-Asset is -0.04. AbbVie's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For AbbVie (ABBV), the current Equity-to-Asset is -0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (ABBV) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of $249.46 is trading 14.1% above its estimated GF Value™ of $218.61.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for ABBV:
Equity-to-Asset: -0.04
GF Value™: $218.61 vs. price of $249.46 (14.1% above fair value)
No single metric tells the full story. See the ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
77GF Score
Get the complete analysis for ABBV
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABBV has been successfully added to your 
